Deal Rationale McKesson’s strategic focus on disciplined portfolio management involves continuous evaluation of its business segments to ensure alignment with its growth priorities and optimize ...

I reiterate a Strong Buy rating on McKesson Corporation with a fair value of $828 per share, driven by robust growth in the oncology and biopharma sectors. McKesson posted 19% revenue growth and ...

McKesson MCK1.06%increase; green up pointing triangle plans to separate its medical-surgical business into a new company. The pharmaceutical distributor on Thursday said the new company would be a ...

McKesson (MCK) came out with quarterly earnings of $10.12 per share, beating the Zacks Consensus Estimate of $9.81 per share. This compares to earnings of $6.18 per share a year ago. These figures ...

Healthcare distributor and services company McKesson (NYSE:MCK) will be reporting earnings tomorrow after market hours. Here’s what you need to know. McKesson missed analysts’ revenue ...

McKesson has consistently grown ahead of the broader market in recent years. The stock’s steady earnings should attract safety-minded investors in the current climate. Margins could edge higher ...

McKesson (MCK) CEO Brian Tyler disclosed the sale of 8,961 shares at an average price of $597.99 for a total amount of $5.36M. The share sales included 10b5-1 plan transactions. Tyler still owns ...

McKesson (NYSE:MCK) is one of the three main drug distribution firms in the United States. The company has more than 50,000 employees and generates around $350 billion in annual revenues, making ...

McKesson, a massive company that distributes pharmaceuticals and medical supplies, is laying off 83 employees and permanently closing a medical-surgical distribution center in Rogers, the company ...

NEW YORK, March 12 (Reuters) - A federal appeals court on Tuesday revived a lawsuit by a whistleblower who accused McKesson (MCK.N), opens new tab of providing drug pricing tools to doctors for ...

IRVING, Texas--(BUSINESS WIRE)--McKesson released its latest Impact Report for fiscal years 2022 and 2023, showcasing our ongoing commitment to advancing health outcomes for all. The report ...

Analysts have provided the following ratings for McKesson (NYSE:MCK) within the last quarter: These 4 analysts have an average price target of $420.25 versus the current price of McKesson at $378. ...